Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOVX GeoVax Labs	$0.98 -2.3%	$1.29	$0.73 ▼ $11.18	$13.52M	3.7	600,025 shs	892,041 shs
IXHL Incannex Healthcare	$0.58 -7.1%	$0.88	$0.47 ▼ $3.55	$10.38M	7.54	62,607 shs	14,260 shs
NOVN Novan		$0.00	$0.08 ▼ $3.33	$2.64M	-0.06	602,421 shs	7.19 million shs
SCNX Scienture	$0.99 +4.2%	$1.57	$0.69 ▼ $9.55	$12.39M	2.82	1.21 million shs	64,128 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOVX GeoVax Labs	+17.92%	+20.55%	-27.01%	-51.69%	-35.06%
IXHL Incannex Healthcare	+5.95%	+2.48%	-14.95%	-64.28%	-72.34%
NOVN Novan	0.00%	0.00%	0.00%	0.00%	+11,662.50%
SCNX Scienture	+8.19%	+9.47%	-46.33%	-77.75%	+94,989,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOVX GeoVax Labs	2.4761 of 5 stars	3.6	2.0	0.0	0.0	1.7	1.7	1.3
IXHL Incannex Healthcare	0.6271 of 5 stars	0.0	5.0	0.0	0.0	0.6	1.7	0.0
NOVN Novan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOVX GeoVax Labs	3.29	Buy	$12.90	1,220.64% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
NOVN Novan	0.00	N/A	N/A	N/A
SCNX Scienture	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NOVN, IXHL, GOVX, and SCNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
2/27/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
1/31/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOVX GeoVax Labs	$3.95M	3.42	N/A	N/A	$3.24 per share	0.30
IXHL Incannex Healthcare	$98K	105.88	N/A	N/A	$0.05 per share	11.62
NOVN Novan	$24.71M	0.00	N/A	N/A	$0.19 per share	0.00
SCNX Scienture	$136.64K	90.67	N/A	N/A	$0.45 per share	2.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOVX GeoVax Labs	-$25.97M	-$5.67	N/A	N/A	N/A	N/A	-809.87%	-349.34%	5/13/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.39	N/A	∞	N/A	N/A	-289.30%	-154.96%	5/21/2025 (Estimated)
NOVN Novan	-$31.31M	-$1.32	N/A	N/A	N/A	-128.61%	-700.28%	-39.58%	N/A
SCNX Scienture	-$17.84M	N/A	0.00	∞	N/A	N/A	-77.60%	-62.29%	6/24/2025 (Estimated)

Latest NOVN, IXHL, GOVX, and SCNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	N/A	N/A	N/A	$0.16 million	N/A
5/13/2025	Q1 2025	GOVX GeoVax Labs	-$0.51	N/A	N/A	N/A	$1.75 million	N/A
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million
2/14/2025	Q2 2025	IXHL Incannex Healthcare	N/A	-$0.33	N/A	-$0.33	N/A	$10.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
NOVN Novan	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOVX GeoVax Labs	N/A	4.17	4.17
IXHL Incannex Healthcare	2.47	1.80	1.65
NOVN Novan	N/A	0.74	0.72
SCNX Scienture	0.03	1.34	1.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOVX GeoVax Labs	6.09%
IXHL Incannex Healthcare	0.43%
NOVN Novan	14.51%
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
GOVX GeoVax Labs	5.70%
IXHL Incannex Healthcare	26.53%
NOVN Novan	1.30%
SCNX Scienture	49.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOVX GeoVax Labs	10	13.84 million	8.90 million	Not Optionable
IXHL Incannex Healthcare	3	17.86 million	13.12 million	Not Optionable
NOVN Novan	90	28.02 million	27.65 million	Not Optionable
SCNX Scienture	N/A	12.52 million	4.40 million	N/A

NOVN, IXHL, GOVX, and SCNX Headlines

Recent News About These Companies

Scienture initiates supply chain activities by subsidiary to launch Arbli

April 24 at 9:09 PM | markets.businessinsider.com

Scienture Holdings, Inc. Announces Supply Chain Readiness for Launch of FDA-Approved ArbliTM Oral Suspension in July 2025

April 22 at 8:19 AM | quiverquant.com

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

April 22 at 8:05 AM | globenewswire.com

Scienture Holdings Divests Subsidiaries to Tollo Health

April 11, 2025 | tipranks.com

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment ...

April 10, 2025 | seekingalpha.com

Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M

April 10, 2025 | markets.businessinsider.com

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

April 8, 2025 | globenewswire.com

Scienture files to sell 2.64M shares of common stock for holders

April 5, 2025 | markets.businessinsider.com

Scienture CEO says focused on execution, growth, expansion for years ahead

April 4, 2025 | markets.businessinsider.com

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

April 3, 2025 | globenewswire.com

SCNX Scienture Holdings, Inc.

April 2, 2025 | seekingalpha.com

Scienture appoints Rath as CCO, enters agreement with Syneos

March 26, 2025 | markets.businessinsider.com

Scienture Holdings, Inc. Appoints Michele Rath as Senior Vice President and Chief Commercial Officer

March 25, 2025 | quiverquant.com

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

March 25, 2025 | globenewswire.com

Scienture announces draaw on Equity Line of Credit

March 20, 2025 | markets.businessinsider.com

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

March 19, 2025 | taiwannews.com.tw

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

March 19, 2025 | globenewswire.com

Scienture announces U.S. FDA approval of NDA for SCN-102

March 19, 2025 | markets.businessinsider.com

FDA Approves ArbliTM, the First Ready-to-Use Oral Liquid Formulation of Losartan, from Scienture Holdings, Inc.

March 18, 2025 | quiverquant.com

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

March 18, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NOVN, IXHL, GOVX, and SCNX Company Descriptions

GeoVax Labs NASDAQ:GOVX

$0.98 -0.02 (-2.32%)

As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Incannex Healthcare NASDAQ:IXHL

$0.58 -0.04 (-7.05%)

Closing price 03:59 PM Eastern

Extended Trading

$0.59 +0.01 (+1.38%)

As of 07:30 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Novan NASDAQ:NOVN

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

Scienture NASDAQ:SCNX

$0.99 +0.04 (+4.22%)

Closing price 04:00 PM Eastern

Extended Trading

$0.96 -0.03 (-2.53%)

As of 07:45 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time